Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Northbrook, Illinois Clinical Trials

A listing of Northbrook, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (368) clinical trials

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

PRIMARY OBJECTIVES: I. To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions. SECONDARY OBJECTIVES: I. To determine the safety profile of 160 mg once daily (QD) dose of AZD9291 (osimertinib) in patients with EGFR Exon 20 insertion mutations. II. To determine the ...

Phase

4.27 miles

Learn More »

Nivolumab Cabozantinib S-Malate and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To demonstrate whether combination therapy of nivolumab and cabozantinib s-malate (cabozantinib), or of nivolumab and cabozantinib, and ipilimumab as compared to nivolumab alone, extends progression-free survival (PFS) for this patient population with non-squamous non-small cell lung cancer (NSCLC). SECONDARY OBJECTIVES: I. To estimate the overall survival for ...

Phase

4.27 miles

Learn More »

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

Prospective, post-market surveillance program to be conducted in the United States (US). Infant will be invited to enroll by their healthcare provider who recommends the use of a free amino acid based infant formula

Phase N/A

4.53 miles

Learn More »

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

4.55 miles

Learn More »

An Open-Label Phase 3 Study to Examine the Long-Term Safety Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to evaluate the long-term safety, tolerability and efficacy of APL-130277.

Phase

4.88 miles

Learn More »

Additional Post Hoc Analysis and Clinical Data Collection

To collect additional Investigational cognitive tasks and additional clinical data for subjects tested with ElMindA's Brain Network Activation (BNA). The BNA technology was developed and is utilized by ElMindA Ltd. The (BNA) Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the ...

Phase N/A

4.88 miles

Learn More »

Phase 2/3 Randomized Double-Masked Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

This is a double masked, randomized, sham-controlled efficacy and safety study that will enroll approximately 800 subjects with recent-onset NAION. Subjects will be randomized into one of 3 groups in a 1:1:1 ratio, and assigned to receive QPI-1007 and/or a sham procedure. Subjects will have a two in three (66%) ...

Phase

4.88 miles

Learn More »

InnFocus MicroShunt Versus Trabeculectomy Study

This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity. Clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to ...

Phase

4.88 miles

Learn More »

Treatment for CI-DME in Eyes With Very Good VA Study

Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes with poor visual acuity, such as a visual acuity letter score of 78 or worse (approximate Snellen equivalent ...

Phase

4.88 miles

Learn More »

Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)

Parkinson's disease (PD) is a common, neurodegenerative condition. Although mostly a late-onset disorder, 10 percent of people with PD are reported to develop symptoms before the age of 50. To date, six genes have been found to be associated with PD, however the majority have been found in rare PD ...

Phase N/A

4.88 miles

Learn More »